169 related articles for article (PubMed ID: 14627130)
1. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Roos JC; de Bree R; Wilhelm AJ; Kummer JA; Hanft G; Heider KH; Stehle G; Snow GB; van Dongen GA
Cancer Immunol Immunother; 2003 Sep; 52(9):576-82. PubMed ID: 14627130
[TBL] [Abstract][Full Text] [Related]
2. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients.
Stroomer JW; Roos JC; Sproll M; Quak JJ; Heider KH; Wilhelm BJ; Castelijns JA; Meyer R; Kwakkelstein MO; Snow GB; Adolf GR; van Dongen GA
Clin Cancer Res; 2000 Aug; 6(8):3046-55. PubMed ID: 10955783
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer.
Koppe M; Schaijk Fv; Roos J; Leeuwen Pv; Heider KH; Kuthan H; Bleichrodt R
Cancer Biother Radiopharm; 2004 Dec; 19(6):720-9. PubMed ID: 15665619
[TBL] [Abstract][Full Text] [Related]
4. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer.
de Bree R; Roos JC; Quak JJ; den Hollander W; Snow GB; van Dongen GA
Clin Cancer Res; 1995 Jun; 1(6):591-8. PubMed ID: 9816020
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution of radiolabeled monoclonal antibody E48 IgG and F(ab')2 in patients with head and neck cancer.
de Bree R; Roos JC; Quak JJ; den Hollander W; Wilhelm AJ; van Lingen A; Snow GB; Dongen GA
Clin Cancer Res; 1995 Mar; 1(3):277-86. PubMed ID: 9815983
[TBL] [Abstract][Full Text] [Related]
7. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
[TBL] [Abstract][Full Text] [Related]
8. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
[TBL] [Abstract][Full Text] [Related]
9. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts.
Verel I; Heider KH; Siegmund M; Ostermann E; Patzelt E; Sproll M; Snow GB; Adolf GR; van Dongen GA
Int J Cancer; 2002 May; 99(3):396-402. PubMed ID: 11992408
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma.
Riechelmann H; Sauter A; Golze W; Hanft G; Schroen C; Hoermann K; Erhardt T; Gronau S
Oral Oncol; 2008 Sep; 44(9):823-9. PubMed ID: 18203652
[TBL] [Abstract][Full Text] [Related]
11. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
13. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
Tijink BM; Buter J; de Bree R; Giaccone G; Lang MS; Staab A; Leemans CR; van Dongen GA
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6064-72. PubMed ID: 17062682
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck.
Sauter A; Kloft C; Gronau S; Bogeschdorfer F; Erhardt T; Golze W; Schroen C; Staab A; Riechelmann H; Hoermann K
Int J Oncol; 2007 Apr; 30(4):927-35. PubMed ID: 17332932
[TBL] [Abstract][Full Text] [Related]
15. Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients.
de Bree R; Roos JC; Plaizier MA; Quak JJ; van Kamp GJ; den Hollander W; Snow GB; van Dongen GA
Br J Cancer; 1997; 75(7):1049-60. PubMed ID: 9083342
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution of 131I-labeled anti-CK8 monoclonal antibody in HNSCC in xenotransplanted SCID mice.
Andratschke M; Luebbers CW; Johannson V; Schmitt B; Mack B; Zeidler R; Lang S; Wollenberg B; Gildehaus FJ
Anticancer Res; 2011 Oct; 31(10):3315-21. PubMed ID: 21965741
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.
Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA
Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989
[TBL] [Abstract][Full Text] [Related]
18. Clinical imaging of head and neck cancer with technetium-99m-labeled monoclonal antibody E48 IgG or F(ab')2.
de Bree R; Roos JC; Quak JJ; den Hollander W; van den Brekel MW; van der Wal JE; Tobi H; Snow GB; van Dongen GA
J Nucl Med; 1994 May; 35(5):775-83. PubMed ID: 8176458
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunoscintigraphy of head and neck cancer using 99mTc-labeled monoclonal antibody E48 F(ab')2.
van Dongen GA; Leverstein H; Roos JC; Quak JJ; van den Brekel MW; van Lingen A; Martens HJ; Castelijns JA; Visser GW; Meijer CJ
Cancer Res; 1992 May; 52(9):2569-74. PubMed ID: 1568225
[TBL] [Abstract][Full Text] [Related]
20. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]